STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma, Ocular Hypertension
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Aug 9, 2022 → Apr 18, 2023
NCT ID
NCT05495061About STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% is a phase 3 stage product being developed by Santen Pharmaceutical for Primary Open Angle Glaucoma, Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05495061. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Primary Open Angle Glaucoma, Ocular Hypertension were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05495061 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma, Ocular Hypertension